Immunotherapy and TKIs Boost Survival in Older Adults With AL Leukemia
New chemotherapy-free approaches may double long-term survival in older patients with acute lymphoblastic leukemia
Topology
A shift from traditional chemotherapy to immunotherapy-based regimens, including blinatumomab, inotuzumab, and TKIs like ponatinib, is significantly improving outcomes in older adults with acute lymphoblastic leukemia (ALL), raising survival rates from under 20% to as high as 80%-90% in select groups.
Study Details
At the ASCO 2025 conference, Res…
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.